Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

UBS Analyst Maintains Neutral Rating on Ziff Davis Lowers Price Target to 76

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Finance_ stocks to buy
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On March 5, 2024, analyst Kunal Madhukar from UBS decided to maintain a Neutral rating on Ziff Davis (NASDAQ: ZD) while decreasing the price target to $76. This update comes after a recent adjustment that saw the price target drop from $81 to $71.

It seems that Madhukar is taking a cautious approach to Ziff Davis’s performance, possibly due to changing market conditions or company developments. Investors may want to keep an eye on how Ziff Davis responds to these price target changes in the coming days.

ZD Stock Price Drops by 4.30% on March 5, 2024: Investors Await Rebound Opportunities

On March 5, 2024, ZD stock experienced a significant drop in its price performance. The stock opened at $67.92, which was $0.96 lower than its previous close. Throughout the trading day, the price of ZD shares continued to decline, ultimately dropping by $2.96, or 4.30%, by the time the market closed.

Investors may be keeping a close eye on ZD’s performance in the coming days to see if this downward trend continues or if the stock is able to rebound. It will be important to monitor any news or developments related to the company that could impact its stock price.

Mixed Results in Financial Report for 2023 – SEO Title

On March 5, 2024, ZD stock had a mixed performance as the company released its financial results for the past year and the fourth quarter. According to data from CNN Money, ZD reported total revenue of $1.36 billion for the year, which remained flat compared to the previous year. Additionally, the total revenue for the fourth quarter was reported at $389.88 million, also holding flat compared to the previous quarter.

However, the company’s net income showed a decline in performance. ZD reported a net income of $41.50 million for the year, which represented a decrease of 34.88% compared to the previous year. The net income for the fourth quarter was reported at $63.42 million, holding flat compared to the previous quarter.

Similarly, ZD’s earnings per share (EPS) also showed a decline in performance. The EPS for the year was reported at $0.89, representing a decrease of 34.34% compared to the previous year. The EPS for the fourth quarter was reported at $1.29, holding flat compared to the previous quarter.

Overall, ZD stock showed mixed performances on March 5, 2024. Investors will be closely monitoring the company’s future financial results to see if ZD can improve its performance in the coming quarters.

Tags: ZD
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ projections

Jonathan Painter Sells 23 Million Worth of Kadant Stock

Finance_Assets (2)

SunOpta Receives Buy Rating and Increased Price Target from Analysts

Analyst Sentiment and Actions on Element Solutions NYSE ESI

Recommended

EEFT stock news

Analyst Ratings and Price Targets for Definitive Healthcare

2 years ago
Healthcare Services Stock Exchange

Analyst Ratings and Price Targets for Inari Medical NASDAQNARI

2 years ago
STZ stock news

Analyzing Analyst Recommendations and Target Price for FirstEnergy Corp.

2 years ago
Healthcare-sector

Introducing the Revolutionary Herbalife GLP1 Nutrition Companion

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

Is 3M’s Resurgence Signaling a Sustainable Recovery?

Eastman Chemical’s Challenging Quarter: A Deep Dive into the Numbers

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

Trending

MannKind Stock
Analysis

MannKind Shares Surge on Exceptional Quarterly Performance

by Robert Sasse
November 6, 2025
0

MannKind Corporation witnessed a substantial rally in its share price following the release of its third-quarter 2025...

Amgen Stock

Amgen’s Impressive Quarterly Performance Fuels Investor Confidence

November 6, 2025
Teledyne Stock

An Overlooked AI Contender Emerges in Defense Technology

November 6, 2025
Molina Healthcare Stock

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

November 6, 2025
Nio Stock

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • MannKind Shares Surge on Exceptional Quarterly Performance
  • Amgen’s Impressive Quarterly Performance Fuels Investor Confidence
  • An Overlooked AI Contender Emerges in Defense Technology

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com